<DOC>
	<DOC>NCT00404963</DOC>
	<brief_summary>This study represents the first administration of GSK376501 in humans and the goal is to evaluate its initial safety and tolerability. The way the human body processes GSK376501 will also be determined.</brief_summary>
	<brief_title>A Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects</brief_title>
	<detailed_description>A Single-Blind, Randomized, Placebo Controlled, Ascending Single and Repeat Dose Study with Once Daily Dosing to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK376501 and to Evaluate Food Effects and the Relative Bioavailability of a Tablet Formulation Compared to the Powder for Reconstitution Formulation in Healthy Overweight and Obese Subjects (DIX109177)</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<criteria>Inclusion: Healthy Nonsmoking Overweight or obese subjects with a BMI between 27 and 35. Exclusion: Women who are pregnant, lactating, or are of childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>GSK376501,</keyword>
	<keyword>First Time in Human,</keyword>
	<keyword>Single Dose,</keyword>
	<keyword>Dose Escalation,</keyword>
	<keyword>Healthy Overweight/Obese Volunteer</keyword>
</DOC>